DaVita (DVA), Fresenius Medical (FMS) and Baxter (BAX), which provide kidney dialysis and related services or equipment, are down 15%, 17% and 9%, respectively, in Wednesday pre-market trading after Novo Nordisk (NVO) announced the decision to stop the kidney outcomes trial FLOW studying the effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease. “The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy. Based on the decision to stop the trial at interim, the process of closing the trial will be initiated,” the company stated. Novo Nordisk expects that FLOW will read out during the first half year of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FMS:
- UBS Calls DaVita (NYSE:DVA) Sell-Off “Big Overreaction”
- Dialysis Providers’ Stocks Drop as Novo Nordisk (NYSE:NVO) Halts Ozempic Study
- Attorneys general file complaint against Fresenius Vascular Care
- Fresenius Medical upgraded to Neutral from Sell at UBS
- BJ’s Wholesale names Anjana Harve as chief information officer
Questions or Comments about the article? Write to editor@tipranks.com